

Disclosures

Personal Commercial (10)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------|---|-------------------------------|---|
| Self | | | |
| Abbott Laboratories | Consultant Fees/Honoraria | Significant (\geq \$5,000) | Arrhythmias and Clinical EP |
| American Heart Association | Other - <i>Senior Associate Editor, Circ AE</i> | Significant (\geq \$5,000) | Arrhythmias and Clinical EP |
| Biosense Webster | Consultant Fees/Honoraria | Significant (\geq \$5,000) | Arrhythmias and Clinical EP |
| Biotronik | Consultant Fees/Honoraria | Modest ($<$ \$5,000) | Arrhythmias and Clinical EP |
| Boston Scientific | Consultant Fees/Honoraria | Significant (\geq \$5,000) | Arrhythmias and Clinical EP |
| iRhythm | Consultant Fees/Honoraria | Modest ($<$ \$5,000) | Arrhythmias and Clinical EP |
| Medtronic | Consultant Fees/Honoraria | Significant (\geq \$5,000) | Arrhythmias and Clinical EP |
| Philips/Biotel | Consultant Fees/Honoraria | Modest ($<$ \$5,000) | Arrhythmias and Clinical EP |
| Varian | Consultant Fees/Honoraria | None (\$0) | Arrhythmias and Clinical EP |
| Zoll | Consultant Fees/Honoraria | Modest ($<$ \$5,000) | Arrhythmias and Clinical EP |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (3)

| Trial Name | Trial Sponsor | Trial Funding Source |
|---|-------------------------------|----------------------|
| LESS-VT | Abbott Laboratories | |
| Effects of Flecainide on Cardiac Arrhythmias in ARVC Patients | National Institutes of Health | |
| PIVATAL | National Institutes of Health | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/21/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/21/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/21/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 4/6/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.